European Union antitrust regulators are reportedly leaning towards not soliciting feedback on the proposed remedies by Deutsche Boerse’s energy exchange unit, EEX, to secure approval for its acquisition of Nasdaq’s commodities clearing business. This move, as indicated by sources familiar with the matter, suggests a potentially smoother path for the deal’s approval.
The transaction, which has been under the scrutiny of the European Commission, the EU’s executive arm responsible for enforcing competition laws, is part of EEX’s strategy to expand its footprint in the energy clearing sector. The acquisition aims to integrate Nasdaq’s commodities clearing business, a key player in the market, under EEX’s umbrella, thereby enhancing its offerings and competitive edge in the industry.
Related: EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
Typically, the European Commission seeks input from rivals and customers before making a final decision on such deals, especially when the parties involved propose remedies to address competition concerns. However, in this case, the decision to potentially bypass this step could indicate the Commission’s satisfaction with the remedies proposed by EEX, or a determination that the acquisition does not pose significant competition issues.
While the exact details of the proposed remedies have not been disclosed, the move by EU regulators not to seek further feedback could expedite the approval process, allowing EEX and Nasdaq to proceed with their plans without additional hurdles.
Featured News
FTC Files Suit Against Liquor Giant Southern Glazer’s Over Discount Disparities
Dec 12, 2024 by
CPI
Racing Rivals Accuse NASCAR of Retaliation in High-Stakes Antitrust Battle
Dec 12, 2024 by
CPI
Samsung Challenges Indian Antitrust Investigation, Calls Raid “Unlawful”
Dec 12, 2024 by
CPI
European Sites Criticize Google’s Compliance Efforts with DMA
Dec 12, 2024 by
CPI
Banco BPM Overcomes Regulatory Hurdle in $1.7 Billion Bid
Dec 12, 2024 by
CPI
Antitrust Mix by CPI
Coopetition in The Pharma Industry: Challenges for Antitrust
Dec 12, 2024 by
Juan Delgado & Lourdes Sosa
Symmetry and the Sixth Force: The Essential Role of Complements
Dec 12, 2024 by
Adam Brandenburger & Barry Nalebuff
ESG Collaborations in Light of European Antitrust Policy and Enforcement Trends
Dec 12, 2024 by
Christian Ritz, Julia Gingelmaier & Kyra Harmes
Antitrust Chronicle® – Co-opetition
Dec 11, 2024 by
CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI